Troosters, Thierry
Sciurba, Frank C
Decramer, Marc
Siafakas, Nikos M
Klioze, Solomon S
Sutradhar, Santosh C
Weisman, Idelle M
Yunis, Carla
Article History
Received: 8 September 2013
Revised: 20 December 2013
Accepted: 8 January 2014
First Online: 20 May 2014
Competing interests
: TT has received fees as chair of the steering committee from Pfizer, consultancy fees from AstraZeneca and lecture fees from Boehringer Ingelheim, Chiesi and Novartis. FCS has received grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Forest Pharmaceuticals, Actelion, AstraZeneca, NIH and fees for advisory boards from GlaxoSmithKline, AstraZeneca and PneumRx. MD has received fees for advisory boards from Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Altana, consultancy and lectures fees from Boehringer Ingelheim and GlaxoSmithKline, and grants from AstraZeneca. NMS has received consultancy fees from Novartis, Elpen, AstraZeneca and Pfizer, grants from GlaxoSmithKline and Takeda, and lecture fees from Novartis, Elpen, AstraZeneca and Pfizer. CY is an employee of Pfizer and a shareholder. SK, SCS and IMW were employees of Pfizer at the time of the study but are now currently employed by Novartis Pharmaceuticals, East Hanover, NJ, USA.